1. Market Research
  2. > Biotechnology Market Trends
  3. > Longevity Biotech, Inc - Product Pipeline Review - 2015

Longevity Biotech, Inc - Product Pipeline Review - 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 29 pages

Longevity Biotech, Inc - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Longevity Biotech, Inc - Product Pipeline Review - 2015’, provides an overview of the Longevity Biotech, Inc’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Longevity Biotech, Inc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Longevity Biotech, Inc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Longevity Biotech, Inc’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Longevity Biotech, Inc’s pipeline products

Reasons to buy

- Evaluate Longevity Biotech, Inc’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Longevity Biotech, Inc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Longevity Biotech, Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Longevity Biotech, Inc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Longevity Biotech, Inc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Longevity Biotech, Inc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Longevity Biotech, Inc - Product Pipeline Review - 2015
Table of Contents
Longevity Biotech, Inc Snapshot 5
Longevity Biotech, Inc Overview 5
Key Information 5
Key Facts 5
Longevity Biotech, Inc - Research and Development Overview 6
Key Therapeutic Areas 6
Longevity Biotech, Inc - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Longevity Biotech, Inc - Pipeline Products Glance 11
Longevity Biotech, Inc - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Longevity Biotech, Inc - Drug Profiles 13
Synthetic Peptide to Agonize GLP1/GIP for Metabolic Disorders 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Synthetic Peptide to Inhibit Glycoprotein 41 for HIV 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Synthetic Peptide 1 for Cancer 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Synthetic Peptide 2 for Cancer 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Synthetic Peptide for Metabolic Disorders 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Synthetic Peptide to Agonize VIP for Small Cell Lung Cancer 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Synthetic Peptide to Agonize VPAC2 for Pulmonary Arterial Hypertension 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Synthetic Peptide to Antagonize VPAC1 for Breast and Colon Cancer 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Longevity Biotech, Inc - Pipeline Analysis 22
Longevity Biotech, Inc - Pipeline Products by Target 22
Longevity Biotech, Inc - Pipeline Products by Route of Administration 23
Longevity Biotech, Inc - Pipeline Products by Molecule Type 24
Longevity Biotech, Inc - Pipeline Products by Mechanism of Action 25
Longevity Biotech, Inc - Dormant Projects 26
Longevity Biotech, Inc - Locations And Subsidiaries 27
Head Office 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29

List of Tables
Longevity Biotech, Inc, Key Information 5
Longevity Biotech, Inc, Key Facts 5
Longevity Biotech, Inc - Pipeline by Indication, 2015 8
Longevity Biotech, Inc - Pipeline by Stage of Development, 2015 9
Longevity Biotech, Inc - Monotherapy Products in Pipeline, 2015 10
Longevity Biotech, Inc - Preclinical, 2015 11
Longevity Biotech, Inc - Discovery, 2015 12
Longevity Biotech, Inc - Pipeline by Target, 2015 22
Longevity Biotech, Inc - Pipeline by Route of Administration, 2015 23
Longevity Biotech, Inc - Pipeline by Molecule Type, 2015 24
Longevity Biotech, Inc - Pipeline Products by Mechanism of Action, 2015 25
Longevity Biotech, Inc - Dormant Developmental Projects,2015 26

List of Figures
Longevity Biotech, Inc - Pipeline by Top 10 Indication, 2015 7
Longevity Biotech, Inc - Pipeline by Stage of Development, 2015 9
Longevity Biotech, Inc - Monotherapy Products in Pipeline, 2015 10
Longevity Biotech, Inc - Pipeline by Top 10 Target, 2015 22
Longevity Biotech, Inc - Pipeline by Top 10 Route of Administration, 2015 23
Longevity Biotech, Inc - Pipeline by Top 10 Molecule Type, 2015 24
Longevity Biotech, Inc - Pipeline Products by Top 10 Mechanism of Action, 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted ...

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppresso ...

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cytotoxic T Lymphocyte Protein 4 (Cytotoxic ...

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.